secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-04-14T23:59:59+00:00
Accession:  0001104659-23-045573
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx receives Nasdaq delisting notice for failing to maintain $35M market value
--------------------------------------------------------------------------------

- Received delisting notice on April 11, 2023, for non-compliance with Nasdaq's $35M minimum market value requirement.
- Company failed to regain compliance during the 180-day grace period that ended April 10, 2023.
- Trading will be suspended on April 20, 2023, unless company requests a hearing by April 18, 2023.
- Company intends to appeal; a hearing request will stay the suspension pending Panel decision.
- There is no assurance the appeal will succeed or that continued listing will be granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/0001104659-23-045573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923045573/tm2312848d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-045573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer